BMS’ Opdivo fails to improve overall survival in small-cell lung cancer

pharmafile | October 15, 2018 | News story | Research and Development, Sales and Marketing BMS< Opdivo, Bristol-Myers Squibb, Cancer, lung cancer, pharma 

Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, failing to significantly improve overall survival (OS) in patients who had relapsed following platinum-based chemotherapy.

The trial examined the drug’s efficacy in two randomised groups, with one receiving Opdivo and the other using either topotecan or amrubicin. The primary endpoint was OS, while secondary endpoints included progression-free survival and objective response rates.

Despite being found to not provide sufficient OS benefit versus chemotherapy alone in this indication, the study found the safety profile of the PD-1 inhibitor to be consistent with previous findings.

“Small cell lung cancer is a highly aggressive disease in which significant unmet need remains,” commented Dr Sabine Maier, Development Lead, Thoracic Cancers, Bristol-Myers Squibb. “We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer. We thank the patients, their families, and the physicians involved in the CheckMate -331 study.”

Advertisement

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

HUTCHMED completes enrolment in phase 3 trial for lung cancer

HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …

Lung cancer cells

Graphene-based biosensor to support new lung cancer screening test

HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …

The Gateway to Local Adoption Series

Latest content